PTC Therapeutics (NASDAQ: PTCT) officer sells shares for tax cover

Rhea-AI Filing Summary

PTC Therapeutics, Inc. reported insider share sales by its Chief Technical Ops Officer, Neil Gregory Almstead, related to tax withholding on equity awards. On January 8, 2026, Almstead automatically sold 881 shares of common stock at $76.45 per share under a sell-to-cover election tied to the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs.

On the same date, 59 additional shares of common stock were automatically sold at $76.45 per share, held indirectly through his spouse, to cover taxes on the vesting of 195 RSUs from a January 7, 2022 grant of 780 RSUs. After these transactions, Almstead beneficially owned 115,196 shares directly and 6,791 shares indirectly through his spouse.

Insider Trade Summary

Net Seller: 940 shares ($71,863)

Net Sell 2 txns

Insider Almstead Neil Gregory

Role CHIEF TECHNICAL OPS OFFICER

Sold 940 shs ($72K)

Type	Security	Shares	Price	Value
Sale	Common Stock	881	$76.45	$67K
Sale	Common Stock	59	$76.45	$5K

Holdings After Transaction: Common Stock — 115,196 shares (Direct); Common Stock — 6,791 shares (Indirect, By Spouse)

Footnotes (1)

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs. Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 195 RSUs from a January 7, 2022 grant of 780 RSUs.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Almstead Neil Gregory

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNICAL OPS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		S		881(1)	D	$76.45	115,196	D
Common Stock	01/08/2026		S		59(2)	D	$76.45	6,791	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs.

2. Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 195 RSUs from a January 7, 2022 grant of 780 RSUs.

	/s/ Avraham S. Adler, Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in this PTC Therapeutics (PTCT) Form 4 filing?

The insider is Neil Gregory Almstead, who serves as Chief Technical Ops Officer of PTC Therapeutics, Inc. and is a reporting person for these transactions.

How many PTC Therapeutics (PTCT) shares did the officer sell on January 8, 2026?

On January 8, 2026, Almstead had 881 shares of common stock sold from his direct holdings and 59 shares sold from shares held indirectly by his spouse, all at $76.45 per share.

Why were PTC Therapeutics (PTCT) shares sold in this Form 4?

The footnotes state the sales were automatic sell-to-cover transactions to satisfy tax withholding obligations triggered by the vesting of RSUs granted on January 7, 2022.

How many PTC Therapeutics (PTCT) shares does the officer own after these transactions?

Following the reported sales, Almstead beneficially owned 115,196 shares of common stock directly and 6,791 shares indirectly through his spouse.

Were the spouse’s PTC Therapeutics (PTCT) shares included in this Form 4?

Yes. The filing reports a sale of 59 shares of common stock held indirectly and labeled as owned "By Spouse", also as an automatic sell-to-cover for tax withholding.

What RSU grants are linked to the PTC Therapeutics (PTCT) sell-to-cover transactions?

The automatic sales relate to the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs and the vesting of 195 RSUs from a January 7, 2022 grant of 780 RSUs.